therapeutic class overview of psoriasis | research reports

Report: THERAPEUTIC CLASS OVERVIEW PSORIASIS

Category: Healthcare

www.researchonglobalmarkets.com

Insert ImageHeight - 3.60Width – 4.98

http://bit.ly/therapeutic-psoriasis

http://www.researchonindia.com/

http://www.researchonglobalmarkets.com/

https://www.facebook.com/pages/Research-on-Global-Markets/536186973101152

http://www.linkedin.com/groups?gid=5131467&mostPopular=&trk=tyah

https://twitter.com/researchonglobe


• Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients pain, function and quality of life

• Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients

• The lack of targeted immune therapies other than TNF- inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc)

Report Insights







• Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz in 2012 for patients with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics

• In the last couple of years, the face of healthcare has been changing due to challenges - quality and its affordability and accessibility to the providers and patients

• There is ample room for an efficacious affordable therapy to tap the mild to moderate RA patients population where biologics have not made a dent

Report Insights (Continued)







• Few potential launches are also expected in 2014-2015 (OTEZLA - apremilast, Xeljanz - tofacitinib) and onwards

Report Insights (Continued)







• Executive Summary• Unmet Need in Psoriasis• Specific Unmet Need and Emerging Therapies• Pipeline - Biologics Products• Pipeline - Oral Treatment• Pipeline - Topical Treatments• Commercial Outlook• Disease Overview• Current Treatment Options• Treatment Guidelines For PsA

Table of Contents







• Publish date: Feb 24, 2014• Geographic coverage: Global• Number of Pages: 55• Available format: PDF, CD, Hardcopy• Price for Single User License: USD 1,500• Price for Site License: USD 3,002• Price for Global User License: USD 4,502• Delivery Time: Within 1 business day• Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google

Wallet, PayPal

Report Details







Interested in this report?

About UsResearch on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports

For further information, get in touch with us:E-mail: [email protected]: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600

Industry SegmentsAutomotive & Transport Consumer goods Agriculture

Food and Beverage Energy and Utilities Public Sector

Manufacturing & Construction Healthcare Media & Entertainment

IT, Telecom & Electronics Services Others

To view more details regarding this premium market research report,Please click here




therapeutic class overview of psoriasis | research reports

Documents